David Meek Acquires Shares of Cullinan Therapeutics

David Meek, a notable figure associated with Cullinan Therapeutics, Inc., bought 25,319 shares of the company on June 16, 2026. This insider purchase was conducted at no cost per share, reflecting a significant addition to his holdings in the biotechnology firm.

Insider Buying and Selling at Cullinan Therapeutics, Inc.

Several insiders, including David Meek, made notable share purchases on June 16, 2026. Meek acquired 25,319 shares, while other insiders like Mary Thistle, Stephen Webster, and Anthony Rosenberg also bought the same number of shares each. These transactions were not part of any pre-planned trading program.

Other Institutional Activity in Cullinan Therapeutics

Institutional investors have shown varied interest in Cullinan Therapeutics. BlackRock, Inc. increased its stake by 49,670 shares, bringing its total to approximately 4,449,966 shares valued at about $63.2 million. State Street Corp also raised its holdings significantly, adding 346,777 shares to reach a total of 2,544,115 shares worth roughly $36.2 million.

Cullinan Therapeutics, Inc. Stock Down 33.5%

Shares of Cullinan Therapeutics, Inc. (NasdaqGS: CGEM) are trading around $14.44. The company boasts a market cap of approximately $887.5 million and a beta of 0.007, suggesting low volatility. The stock's 52-week range is between $5.68 and $16.74, with a 50-day moving average of $14.43 and a 200-day moving average of $11.38. Cullinan maintains a strong financial position with a current ratio of 10.28 and a quick ratio of 10.09.

Analysts Set New Price Targets

Analysts remain optimistic about Cullinan Therapeutics, with Wedbush reiterating a buy rating and setting a price target of $37 on June 11, 2026. The consensus among analysts is a strong buy, with an average target price of $31.55 based on 11 opinions.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company focuses on developing innovative therapies for autoimmune diseases and cancer. It is engaged in several clinical trials, including those for CLN-978, Velinotamig, and CLN-049. With a team of 109 employees led by CEO Nadim Ahmed, Cullinan is at the forefront of biopharmaceutical advancements.

Bottom Line

David Meek's recent share purchase in Cullinan Therapeutics highlights insider confidence in the company's future. With a robust pipeline of clinical trials and strong institutional backing, investors are keenly watching the company's progress. As always, remember that these insider transactions are disclosed after the fact and may not reflect current positions.